The AWARD-7 trial (Dulaglutide versus insulin glargine in patients with type 2 diabetes and CKD) was the first RCT to examine the efficacy of GLP-1 RA (dulaglutide) in moderate to severe CKD. The gene discussed is GLP1R; the disease is chronic kidney disease.